Revenue figures are a critical indicator of a company's performance. The reported revenues for BRIUMVI suggest that TG Therapeutics is successfully commercializing its product. This positive news is likely to be well-received by the market, potentially leading to a short-term increase in the stock price. However, the broader market conditions and investor sentiment will also play a role in the actual stock movement.